Same Drug Class

Pravastatin vs Lovastatin

Overview

Pravastatin and lovastatin are both moderate-intensity statins but with very different pharmacokinetic profiles. Pravastatin is hydrophilic with no CYP metabolism; lovastatin is lipophilic with complete CYP3A4 dependence. Their potency is similar, making drug interaction profile the key differentiator.

Mechanism of Action

Both inhibit HMG-CoA reductase. Lovastatin is a prodrug; pravastatin is the active open-acid form. Pravastatin's OATP-mediated hepatic uptake enhances its hepatoselectivity.

Pharmacokinetics

Pravastatin: bioavailability ~17%, no CYP metabolism, half-life ~2 h. Lovastatin: bioavailability ~5%, CYP3A4 (major), half-life 2–3 h, must be taken with meals.

Pharmacodynamics

Both are classified as moderate-intensity statins. Lovastatin 40 mg reduces LDL by ~31%; pravastatin 40 mg reduces LDL by ~29%. At 80 mg, lovastatin achieves ~40% and pravastatin ~34%. The efficacy difference is modest.

Clinical Evidence

Pravastatin has the stronger outcome trial record: WOSCOPS (primary prevention), CARE, LIPID, and PROSPER (elderly). Lovastatin's AFCAPS/TexCAPS provides primary prevention data. Neither has the extensive outcome data of atorvastatin.

Safety

Lovastatin 80 mg carries the same FDA restriction as simvastatin 80 mg. Pravastatin lacks such restrictions. Pravastatin is the better-studied statin in elderly populations and has a well-established safety record in renal transplant patients.

Key Takeaways

  • Comparable moderate-intensity potency
  • Pravastatin: no CYP interactions, hydrophilic, preferred in polypharmacy
  • Lovastatin: CYP3A4-dependent, food-dependent absorption, 80 mg restricted
  • Pravastatin has stronger outcome trial evidence overall

Fazit

Pravastatin is preferred over lovastatin when drug interactions are a concern. For simple cases without polypharmacy, either is appropriate at moderate doses, though pravastatin has a stronger evidence base in outcome trials.